Photodynamic and Pharmacologic Treatment of CNV

Photodynamic and Pharmacologic Treatment of Choroidal Neovascularization (Photodynamic Booster Study)

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00570193

Acronym

PBS

Enrollment

Registered

2007-12-10

Start date

2006-12-31

Completion date

2011-06-30

Last updated

2012-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Choroidal Neovascularization, Macular Degeneration

Brief summary

The goal of this pilot study is to validate the use of the combination of Lucentis (ranibizumab) and Visudyne (verteporfin) in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and to explore the use of a volumetric analysis of the CNV lesion to determine disease activity, response to therapy, and as a tool for determining the need for retreatment.

Interventions

DRUGverteporfin (Visudyne)

Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1

DRUGranibizumab (Lucentis)

ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33&37 per study protocol

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* All previously untreated CNV secondary to MD

Design outcomes

Primary

Measure	Time frame
Visual change	18 months

Secondary

Measure	Time frame
Frequency of treatment	18 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026